Erythrocyte Patents (Class 424/93.73)
-
Publication number: 20130195751Abstract: Provided are a self-assembled conjugate of a host molecule containing compound and a guest molecule containing compound, a delivery composition of a bioactive material comprising the self-assembled conjugate and a bioactive material to be delivered, and a composition for tissue engineering containing the self-assembled conjugate and a cell.Type: ApplicationFiled: January 31, 2012Publication date: August 1, 2013Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Sei Kwang HAHN, Kimoon KIM, Hyuntae JUNG, Jeong-A YANG, Kyeng Min PARK
-
Publication number: 20130177541Abstract: Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.Type: ApplicationFiled: November 3, 2011Publication date: July 11, 2013Inventors: Edwin L. Madison, Christopher Thanos, Grant Ellsworth Blouse
-
Publication number: 20130164340Abstract: The present invention relates to biocompatible polymeric scaffold materials, methods for making the materials and methods of using the materials. More particularly, the present invention relates to implants and grafts comprising polymeric scaffold materials of cross-linked human tropoelastin polypeptides and methods of making and using the same. In addition, the present invention provides alternatively spliced tropoelastin polynucleotides and polypeptides.Type: ApplicationFiled: September 28, 2012Publication date: June 27, 2013Applicant: PROTEIN GENOMICS, INC.Inventor: Protein Genomics Inc.
-
Patent number: 8431117Abstract: The present invention provides erythrocytes or nucleated erythrocyte precursors from animals or patients with at least one S hemoglobin allele which are capable of selectively localizing in tumor vasculature resulting in vaso-occlusion, hemolysis and heme release. A tumoricidal effect is achieved when these cells are administered in before during or after administration of (i) an agent(s) that interferes with degradation of reactive oxygen species, (ii) impairs glucose uptake and/or (iii) chemotherapy. These cells also carry oncolytic viruses, antitumor proteins, multidrug resistant proteins, chemotherapy, monoclonal antibodies, superantigens, superantigen conjugates and fusion proteins, siRNAs, plasmids and non-protein toxins and attenuated tumoricidal bacterial cells specifically into the tumors and induce a tumoricidal effect.Type: GrantFiled: February 7, 2012Date of Patent: April 30, 2013Inventor: David S Terman
-
Publication number: 20130064865Abstract: A method of treating a patient who has extravasation of blood from an intravascular compartment to an extravascular compartment. An agent is administered to the patient which mitigates a harmful effect of break-down products of blood at an extravascular site, resulting in the patient having reduced morbidity and mortality. The morbidity and mortality of the patient is further reduced by concomitant administration of a suspension of submicron protein spheres having a molecular weight of ranging from 780 billion Daltons to less than 0.8 billion Daltons.Type: ApplicationFiled: September 6, 2012Publication date: March 14, 2013Inventor: Richard C.K. Yen
-
Publication number: 20130011446Abstract: The invention is directed toward a sterile formable implant composition for application to a bone defect site comprising bioactive glass particles in an aqueous carrier solution, the bioactive glass particles being added to a viscous carrier at a concentration ranging from about 68% to about 76% (w/w), the carrier comprising a mixture of glycerol and polyethylene glycol ranging from 24% to 32% (w/w) with the ratio of glycerol to polyethylene glycol ranging from about 45:55 to about 65:35.Type: ApplicationFiled: September 13, 2012Publication date: January 10, 2013Inventor: Carl Alexander DePaula
-
Publication number: 20120308540Abstract: Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.Type: ApplicationFiled: November 3, 2011Publication date: December 6, 2012Inventors: Edwin L. Madison, Christopher Thanos, Grant Ellsworth Blouse
-
Publication number: 20120230969Abstract: Extracorporeal blood treatment is performed daily on a large number of patients by use of for example a dialysis filter, plasma filter or a centrifuge. The purpose of the treatment is to separate minor components and molecules in a liquid or in the blood from larger ones, for example in connection with different disease conditions or with a view to extracting blood plasma, target substances such as blood components or molecules from for example blood donors. According to the present invention two separation steps are used together with a solution or a suspension containing at least one component, which specifically may bind to the component or the blood component to be specifically reduced, or to be refined/extracted during the treatment or during the blood treatment.Type: ApplicationFiled: October 18, 2010Publication date: September 13, 2012Applicant: GLYCOREX ABInventor: Kurt G. I. Nilsson
-
Publication number: 20120225045Abstract: Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.Type: ApplicationFiled: February 29, 2012Publication date: September 6, 2012Applicant: ONCOLYTICS BIOTECH INC.Inventors: Donald Morris, Bradley G. Thompson, Matthew C. Coffey
-
Publication number: 20120213754Abstract: An apparatus for the preparation of cells for implantation into a living body is disclosed. The apparatus comprises a vessel substantially impermeable to gaseous oxygen; and fluid within said vessel, the fluid having a maximal dissolved oxygen capacity substantially equivalent to normal saline yet having a hypoxic oxygen concentration between about 0% to about 5% of said maximal dissolved oxygen capacity. The bag oxygen concentration level remains low when the apparatus is stored at 22°-25° C. in normal atmospheric conditions for a period of at least 30 days. The present invention simplifies the process of achieving donor cell hypoxic preconditioning for cell implantation, and may be used to bathe said cells to be transplanted for a sufficient time to activate the hypoxic metabolic pathway.Type: ApplicationFiled: February 16, 2012Publication date: August 23, 2012Applicant: STEM CELL PARTNERS LLCInventor: John R. Chapman
-
Publication number: 20120195869Abstract: The present invention provides erythrocytes or nucleated erythrocyte precursors from animals or patients with at least one S hemoglobin allele which are capable of selectively localizing in tumor vasculature resulting in vaso-occlusion, hemolysis and heme release. A tumoricidal effect is achieved when these cells are administered in before during or after administration of (i) an agent(s) that interferes with degradation of reactive oxygen species, (ii) impairs glucose uptake and/or (iii) chemotherapy. These cells also carry oncolytic viruses, antitumor proteins, multidrug resistant proteins, chemotherapy, monoclonal antibodies, superantigens, superantigen conjugates and fusion proteins, siRNAs, plasmids and non-protein toxins and attenuated tumoricidal bacterial cells specifically into the tumors and induce a tumoricidal effect.Type: ApplicationFiled: February 7, 2012Publication date: August 2, 2012Inventor: David S. Terman
-
Publication number: 20120177610Abstract: Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Antitrypsin (A1AT) or a combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins. A complex of all proteins found currently in Plasma, Cryoprecipitate, Fraction III and many newly found proteins now being identified or any substances which are known proteins or unknown proteins which contain GOOD HEALTHY CELLS and the combination of any of these known or unknown proteins which contain any one of these GOOD HEALTHY cells: Neutrophil, Lymphocyte, Eosinophil, Basophil, and Marcophage, and their potential applications for treating a wide variety of diseases and other physical conditions and disorders, and for maintaining health.Type: ApplicationFiled: May 24, 2011Publication date: July 12, 2012Inventor: Kieu Hoang
-
Publication number: 20120148577Abstract: A lymphocytotoxic, but hematopoietic stem cell-sparing, high-dose amount of an oxazaphosphorine drug such as, for example, cyclophosphamide, administered post-transplantation can be used to reduce transplant rejection, including graft-versus-host-disease (GVHD). In some embodiments, the transplants are bone marrow transplants or hematopoietic stem cell transplants carried out for the treatment of hematologic disorders, including hematologic malignancies and non-malignant hematologic disorders. In some embodiments, the transplants are carried out for the treatment of hereditary hemoglobinopathies, such as sickle cell anemia and thalassemia.Type: ApplicationFiled: October 13, 2011Publication date: June 14, 2012Applicants: ACCENTIA BIOPHARMACEUTICALS, INC., JOHNS HOPKINS UNIVERSITYInventors: EPHRAIM J. FUCHS, LEO LUZNIK, ROBERT A. BRODSKY, RICHARD J. JONES, FRANCIS E. O'DONNELL, JR., CARLOS SANTOS, SUSAN BONITZ
-
Publication number: 20120141540Abstract: Red blood cells can be used as effective drug delivery systems when they contain proteins that do not readily diffuse out and which form affinity complexes with the desired drug.Type: ApplicationFiled: June 7, 2010Publication date: June 7, 2012Inventors: Mauro Magnani, Luigia Rossi, Sara Biagiotti, Marzia Bianchi
-
Publication number: 20120134975Abstract: Modified red blood cells are described. In an embodiment, the modified red blood cell includes a target-binding agent. Targeted delivery of imaging agents, drugs, and peptide and protein pharmaceuticals using modified red blood cells are described. Processes for preparing the modified red blood cells, pharmaceutical and diagnostic compositions containing the same and methods of diagnosis and treatment involving the modified red blood cells are described.Type: ApplicationFiled: August 13, 2008Publication date: May 31, 2012Inventors: Roderick A. Hyde, Muriel Y. Ishikawa, Edward K.Y. Jung, William Gates, Alois A. Langer, Eric C. Leuthardt, Royce A. Levien, Clarence T. Tegreene, Thomas A. Weaver, Charles Whitmer, Lowell L. Wood, JR., Victoria Y.H. Wood
-
Publication number: 20120082715Abstract: A composition comprising a glassified, stabilized particle preparation having a low water activity (between about 0.1 and 0.9) is provided. The preparations provide improved products with enhanced storage stability, less expensive cost of processing, and extended shelf life. The glassified, stabilized particle preparations are particularly efficacious in the preparation of perishable products, especially pharmaceutical agents, such as human blood and blood products (e.g., red blood cells). A single emulsion process comprising a 2-phase system for preserving food and pharmaceutical products is also provided. Stabilized biological products as glassified beads are also provided, as well as a method for rehydrating and/or reconstituting the glassified beads to provide useful and fully active reconstituted and/or rehydrated materials is also presented.Type: ApplicationFiled: September 2, 2011Publication date: April 5, 2012Inventor: David Needham
-
Publication number: 20120076750Abstract: The present invention provides a non-liquid biomaterial that may be used as a surgical sealant, a suture support, a blood flow controller, an adhesion reducing agent, an adhesion preventing agent, a tissue support, a tissue filler, a wound dressing or a combination thereof. The non-liquid biomaterial may comprise a blood derived material such as plasma, platelet poor plasma, platelet rich plasma or a material derived from blood containing tissue aspirate, such as bone marrow aspirate, a protein binding agent and a polymerizing agent. Methods for making and using the non-liquid biomaterial are also provided.Type: ApplicationFiled: December 7, 2011Publication date: March 29, 2012Inventors: Hillary Enyart, Jacy Hoeppner, Mike Leach, Shon Steger, Sona Sundaramurthy
-
Patent number: 8105632Abstract: Compositions comprising membrane-derived and synthetic microparticles that induce platelet aggregation and are useful for treating bleeding disorders, particularly those involving platelet dysfunction. Microparticles include endothelial derived microparticles (EMP), platelet derived microparticles (PMP), erythrocyte derived microparticles (RMP), and synthetic microparticles (SMP), and are used to treat disorders such as thrombocytopenia caused by chemotherapy.Type: GrantFiled: December 7, 2005Date of Patent: January 31, 2012Assignee: University of MiamiInventors: Wenche Jy, Joaquin J. Jimenez, Lawrence L. Horstmann, Yeon S. Ahn, Eugene Ahn
-
Publication number: 20120016489Abstract: Implantable pliable bone blocks comprising a solid block of cortical bone characterized by a length, width and thickness, having a first and a second face on opposite sides of the block. The first and second faces have a plurality slot features. The angle of incidence of the slot features of the first face and the x-axis and the angle of incidence of the slot features of the second face and the x-axis (a2) are such that the slots would intersect if they were in the same plane. Methods are provided for making implantable pliable bone blocks.Type: ApplicationFiled: July 16, 2010Publication date: January 19, 2012Applicant: EBI, LLCInventor: Bradford J. COALE
-
Publication number: 20110300193Abstract: A liquid plasma expander or resuscitation fluid composition for use in a subject in need thereof, comprising, consisting of, or consisting essentially of: (a) a keratin derivative (preferably alpha keratose, gamma keratose, or combinations thereof, and with basic alpha keratose preferred over acidic alpha keratose); and (b) an electrolyte solution, with the keratin derivative solubilized in the electrolyte solution to form a homogeneous liquid composition. Blood substitutes formed therefrom and methods of making and using the same are also described.Type: ApplicationFiled: August 11, 2011Publication date: December 8, 2011Inventor: Mark E. Van Dyke
-
Publication number: 20110286987Abstract: The present invention provides improved methods for treating red blood cell compositions with a pathogen-inactivating compound under conditions which provide suitable pathogen inactivation while maintaining cell vitality. Also provided methods of reducing dehydration in red blood cells, as well as treated red blood cell compositions.Type: ApplicationFiled: April 9, 2009Publication date: November 24, 2011Inventors: Naheed Mufti, Anna Erickson, Anne North
-
Publication number: 20110262415Abstract: The invention relates to a cell-based drug delivery system comprising magneto nanoparticles, erythrocytes and a fusion-protein, its preparation and uses thereof in particular as a delivery system for biologically active compounds.Type: ApplicationFiled: December 18, 2009Publication date: October 27, 2011Applicant: CNR - CONSIGLIO NAZIONALE DELLE RICERCHEInventors: Settimio Grimaldi, Antonella Lisi, Caterina Cinti
-
Publication number: 20110177045Abstract: A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.Type: ApplicationFiled: March 31, 2011Publication date: July 21, 2011Inventors: Timothy R. Varney, Charles Randal Mills, Alla Danilkovitch
-
Publication number: 20110177036Abstract: The present invention relates to a whole-blood culture containing specific immunocompetent killer cells that are activated against tumor cells, viruses, bacteria and/or allergens, whereby the whole-blood culture consists of whole-blood and a culture medium at a ratio of 3:1 to 4:1, whereby the culture medium has an oxygen excess of at least 100% or more and contains a water-soluble emulsification product comprising a mixture of phospholipids, vitamin E, and low-molecular proteoglycans with a molecular weight of 1,200 to 12,000 Dalton, and whereby dead tumor cells or fragments thereof and/or viral and/or bacterial antigens and/or allergens have been added to the whole-blood culture [to serve] as antigen in the specific recognition process for production of the activated killer cells (stimulation). The invention also relates to a method for producing the culture, as well as stimulants for the whole-blood culture and a method for the selection thereof.Type: ApplicationFiled: January 31, 2011Publication date: July 21, 2011Inventors: Horst KIEF, Thorsten Kief
-
Publication number: 20110086012Abstract: A rejuvenation method includes a) removing blood or tissue from a human body or animal body, b) nurturing and purifying the blood or tissue, and c) implanting the blood or tissue that has been nurtured and purified into a user to increase the amount of stem cells in the user and to recover degraded organs in the user. Thus, the rejuvenation method is used to increase the number of the stem cells in the user successively so that the degraded organs in the user are repaired and recovered completely and can be returned to the optimum state so as to achieve the rejuvenation purpose. In addition, the blood or tissue is removed and taken from the user's body without causing a rejection.Type: ApplicationFiled: October 13, 2009Publication date: April 14, 2011Inventor: Yu-Han Wang
-
Publication number: 20110070210Abstract: Decades of investigations were focused on finding “gold standard” for evaluation of plasma dilution and osmolality, blood loss evaluation and prediction of bleeding or transfusion induced changes in hematocrit and hemoglobin concentration. Addressing deficiencies of existing methods, the current invention created new combined mathematical-physiological model applicable to manually operated nomograms and software in medical monitors. The mathematical model HBS Trends is used in blood transfusion and infusion therapy nomogram—HBS Nomogram—which is based on blood hemoglobin concentration and hematocrit. It is also an easy and practical tool for recording and dynamical interpretation of plasma osmolality, blood hemoglobin concentration, hematocrit and mean corpuscular hemoglobin concentration. The HBS Nomogram is a practical system for organizing blood test results in a patient's medical records.Type: ApplicationFiled: August 16, 2010Publication date: March 24, 2011Inventor: Audrius Andrijauskas
-
Publication number: 20110070209Abstract: Acute and chronic diseases of the organs are treated in patients using a rational, multi-tier approach. A patient can be pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells or other cell therapy. The patient can be a fetus treated in utero or removed from the womb. The progress of treatment is monitored by ultrasound, MRI, CAT scan, cardiac echo, EEG, EKG, EMG or blood tests, with growth factor treatment and/or stem cell administration adjusted according to the results of the monitoring or clinical status of the patient.Type: ApplicationFiled: March 31, 2010Publication date: March 24, 2011Inventor: Wayne P. Franco
-
Patent number: 7892726Abstract: The invention provides a method for the sterilization of a biological preparation comprising desired viable biological entities. The method comprises irradiating a dried (e.g. freeze-dried) biological preparation with ionizing or UV radiation at an intensity and for a duration sufficient to reduce the amount or activity of living-matter contaminants in the biological preparation, the intensity and duration selected such that at least part of the desired biological entities in the sample remains viable. The method of the invention is particularly suitable for the reduction of the amount or activity of contaminants such as bacteria or viruses from biological preparations comprising red blood cells or platelets.Type: GrantFiled: June 7, 2005Date of Patent: February 22, 2011Assignee: Core Dynamics LimitedInventors: Yehudit Natan, Tamir Kanias
-
Publication number: 20110014170Abstract: This invention relates to novel ?-galactosidases for the enzymatic removal of the immunodominant monosaccharides on blood products and tissues. Specifically this invention provides a novel family of ?3 glycosidases, used for the enzymatic removal of type B antigens from blood group B and AB reactive blood products, and the Galili antigen from non-human animal tissues, thereby converting these to non-immunogenic cells and tissues suitable for transplantation.Type: ApplicationFiled: February 19, 2010Publication date: January 20, 2011Inventors: Qiyong Peter LIU, Henrik Clausen
-
Publication number: 20110014171Abstract: The invention relates to a suspension of erythrocytes encapsulating a bisphosphonate, for use as a medicament for the prevention and treatment of bone metastases and other bone marrow diseases. It also relates to a suspension of erythrocytes encapsulating a bisphosphonate, in which these erythrocytes have undergone a chemical treatment with an agent such as BS3 so as to promote targeting of the bone marrow.Type: ApplicationFiled: March 10, 2009Publication date: January 20, 2011Inventors: Vanessa Bourgeaux, Yann Godfrin
-
Publication number: 20110002904Abstract: Synovial villi derived explants and related surgical tools used to repair or prevent damage to injured or diseased tissue, including connective tissue. The tools including a harvesting tool for selectively harvesting synovial villi from the joint of patient and a delivery tool having a bulbous end for delivering the synovial villi derived explants while reducing damage to surrounding tissue.Type: ApplicationFiled: August 2, 2010Publication date: January 6, 2011Inventor: Lanny L. Johnson
-
Publication number: 20100323965Abstract: The invention relates to compounds and their use in the treatment of thrombocytopenia resulting from diseases or conditions such as immune thrombocytopenic purpura, cancer chemotherapy, surgery, bone marrow or stem cell transplantation, radiation injury or treatment, chronic viral infection, and pancytopenia. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods for treating such diseases or conditions in a mammal, including a human, by administering to such mammal an effective amount of a selected thrombopoietin receptor agonist.Type: ApplicationFiled: August 10, 2010Publication date: December 23, 2010Applicant: STATegics, Inc.Inventors: Jeffrey R. SPENCER, Juha Punnonen
-
Publication number: 20100322911Abstract: The present invention is directed to methods of delivering macromolecules to a target cell or tissue by microwave irradiation. A target cell or tissue is exposed to one or more macromolecules to be delivered into the desired cell or tissue and irradiated with microwave radiation. The strength or power of the microwave radiation is such that the macromolecules are delivered into the target cell or tissue. Preferably, the strength of the microwave radiation does not significantly impact cell viability in a negative manner (e.g., apoptosis).Type: ApplicationFiled: February 25, 2010Publication date: December 23, 2010Inventors: Qi Long Lu, Pei Juan Lu
-
Publication number: 20100316620Abstract: The invention relates to the prevention and treatment of skeletal manifestation of Gaucher's disease. It relates to a formulation for introducing glucocerebrosidase into the lysosomal compartment of macrophages and/or Gaucher cells in the bone marrow, the formulation comprising glucocerebrosidase encapsulated in erythrocytes. Said erythrocytes may have been subjected to a chemical treatment with an agent so as to promote the targeting of macrophages and/or Gaucher cells in the bone marrow. The treatment may be carried out with a bis(sulphosuccinimidyl) suberate (BS3) solution. The invention also describes drugs and methods for prevention and treatment.Type: ApplicationFiled: June 12, 2008Publication date: December 16, 2010Inventors: Vanessa Bourgeaux, Emmanuelle Dufour, Yann Godfrin
-
Publication number: 20100303781Abstract: The invention provides use of an IdeS polypeptide, or a polynucleotide encoding an IdeS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.Type: ApplicationFiled: June 8, 2006Publication date: December 2, 2010Inventors: Lars Björck, Rikard Holmdahl, Kutty Selva Nandakumar
-
Patent number: 7837997Abstract: Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.Type: GrantFiled: December 18, 2006Date of Patent: November 23, 2010Assignees: Trustees of the University of Pennsylvania, University of Virginia Patent FoundationInventors: Vladimir R. Muzykantov, Abd Al-Roof Higazi, Juan Carlos Murciano, Douglas Cines, Ronald P. Taylor
-
Publication number: 20100284982Abstract: Compositions for transporting L-asparaginase across the cellular membrane of erythrocytes, comprising a low molecular weight protamine peptide. Process of preparation of compositions comprising conjugates of L-asparaginase and a low molecular weight protamine peptide. Method of treatment comprising administration of adapted L-asparaginase is also described.Type: ApplicationFiled: December 22, 2008Publication date: November 11, 2010Inventors: Victor C. Yang, Young M. Kwon, Hee S. Chung, Arthur J. Yang
-
Publication number: 20100255059Abstract: A micro-scale artificial gland is disclosed in the form of an independent unit for promoting biological activity. The artificial gland includes cells formed in a membrane enclosing a reservoir. The reservoir is a bio-reactor capable of containing a product of activity of the cells. The reservoir comprises a gas, a liquid, and a gel and preferably also contains nanoparticles, a buffer, a surfactant, and, a gel precursor. The reservoir may also contain cells. Nanoparticles may also surround the artificial gland to form a protective coating. A variety of methods are disclosed for making the artificial gland by directed assembly of cells into the artificial micro-gland by gel, liquid or bubble templating. All involve coating the surface of gel, droplet or bubble with the living cells and the stabilizing the cells on the surface of gels, droplets or bubbles.Type: ApplicationFiled: March 17, 2010Publication date: October 7, 2010Applicant: YNANO, LLCInventors: Manuel Marquez, Samantha M. Marquez, Antonio Garcia
-
Publication number: 20100226903Abstract: A method of delivering therapy to a target site. The method includes (a) obtaining a base image of the target site, (b) injecting a dose of a mix of a therapeutic agent and a contrast agent into a first injection location at the target site via a needle passing through a catheter, (c) collecting sequential fluoroscopic images of a contrast agent dispersion cloud at the first injection location, (d) determining a contrast agent dispersion area from the sequential fluoroscopic images, (e) determining a therapeutic agent dispersion area from the contrast agent dispersion area, (f) marking the therapeutic agent dispersion area on the base image of the target site, and (g) repeating (b) through (f) until the target site is substantially covered with overlapping therapeutic agent dispersion areas corresponding to a plurality of injections at a plurality of injection locations at the target site.Type: ApplicationFiled: March 9, 2009Publication date: September 9, 2010Applicant: Medtronic, Inc.Inventors: Mary M. Morris, Kenneth Gardeski, Laurent Verard, Kevin Thomas Wu, Michael R. Neidert
-
Publication number: 20100166742Abstract: The present invention relates to an ex vivo method for increasing the effectiveness of antibodies and Fc? receptor-binding active ingredients, comprising the steps of: a) preparing a blood sample of a patient; b) subjecting the blood sample to an immunoapheresis; c) administering a therapeutically effective antibody or an Fc? receptor-binding active ingredient to the patient.Type: ApplicationFiled: September 7, 2007Publication date: July 1, 2010Applicant: FRESENIUS MEDICAL CARE DEUTSCHLAND GmbHInventors: Martin Hepper, Hans Peter Leinenbach, Frank Nocken
-
Publication number: 20100158871Abstract: The present invention provides erythrocytes or nucleated erythrocyte precursors from animals or patients with at least one S hemoglobin allele which are capable of selectively localizing in tumor vasculature resulting in vaso-occlusion, hemolysis and heme release. A tumoricidal effect is achieved when these cells are administered in before during or after administration of (i) an agent(s) that interferes with degradation of reactive oxygen species, (ii) impairs glucose uptake and/or (iii) chemotherapy. These cells also carry oncolytic viruses, antitumor proteins, multidrug resistant proteins, chemotherapy, monoclonal antibodies, superantigens, superantigen conjugates and fusion proteins, siRNAs, plasmids and non-protein toxins and attenuated tumoricidal bacterial cells specifically into the tumors and induce a tumoricidal effect.Type: ApplicationFiled: September 22, 2009Publication date: June 24, 2010Inventor: David Stephen Terman
-
Publication number: 20100159011Abstract: The invention relates to composite materials that contain a polymer matrix and aggregates, and in some embodiments, methods of making, and methods of using these materials. Preferably, the aggregates are calcium phosphate aggregates. Preferably, the material is resistant to fracture. In further embodiments, the materials are used in surgical procedures of bone replacement. In further embodiments, the materials contain polyhedral silsesquioxanes and/or biodegradable segments. In further embodiments, the polymer matrix comprises biomolecules.Type: ApplicationFiled: July 31, 2008Publication date: June 24, 2010Inventors: Jane B. Lian, Xinning Li, David C. Ayers, Jie Song
-
Publication number: 20100150893Abstract: The invention features methods for increasing or maintaining the number of functional cells of a predetermined type, for example, insulin producing cells of the pancreas, blood cells, spleen cells, brain cells, heart cells, vascular tissue cells, cells of the bile duct, or skin cells, in a mammal (e.g., a human patient) that has injured or damaged cells of the predetermined type.Type: ApplicationFiled: December 7, 2009Publication date: June 17, 2010Applicant: The General Hospital CorporationInventor: Denise Faustman
-
Publication number: 20100135976Abstract: The invention relates to an adsorption device for removal and/or reduction of undesirable components from blood, such as whole blood, comprising, porous cross-linked polysaccharide particles or beads, wherein the particles or beads have an average size from about 210±50 ?m, at least 30% of the particles have a size from about 180 to about 240 ?m, at least 70% of the particles have a size from about 150 to about 300 ?m and said particles have at least one immobilised ligand, wherein said immobilised ligand have a size of about 150 kD or less. The invention also relates to kits comprising said adsorption device as well as the use of said adsorption device in different applications such as cleaning of blood.Type: ApplicationFiled: June 18, 2007Publication date: June 3, 2010Inventors: Rune Nilsson, Bengt Sandberg
-
Publication number: 20100098675Abstract: A method for treating the side effects resulting from ophthalmic lasery surgery of the eye. The method administers stem cells as a means for treating the destruction of retinal and other tissues resulting from photocoagulation in the treatment of diabetic retinopathy and other eye disorders. Methods for using the invention with other ophthalmic laser surgical procedures, and other eye disorders, are also disclosed.Type: ApplicationFiled: May 29, 2009Publication date: April 22, 2010Inventor: NIKOLAI TANKOVICH
-
Publication number: 20100092444Abstract: Compositions for platelet rich plasma (PRP) are provided. Generally, these compositions comprise a higher concentration of platelets and white blood cells than whole blood. The concentrations of the platelets and/or the white blood cells may be two to eight times the respective concentrations in whole blood. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The PRP composition may be delivered in conjunction with reperfusion therapy.Type: ApplicationFiled: October 8, 2009Publication date: April 15, 2010Applicant: BioParadox, LLCInventor: Allan Kumar Mishra
-
Publication number: 20100086529Abstract: The present invention is drawn to methods of making concentrated fibrinogen- and platelet-containing compositions. The concentrated compositions can be produced by adding a sufficient amount of a fibrinogen precipitating agent, such as protamine or other similar acting agent(s), and a platelet aggregating agent, such as ADP or other similar acting agents(s), to a platelet/fibrinogen containing fluid to cause the fibrinogen to form a fibrinogen precipitate and the platelets to for platelet aggregations. The fibrinogen precipitate and the platelet aggregates are collected by a collection technique, such as filtration, settling, centrifugation, etc., and are solubilized and deaggregated, respectively, in a liquid vehicle to form a concentrated fibrinogen- and platelet-containing composition. The concentrated platelet and/or fibrinogen compositions can be incorporated into systems for making fibrin glues, hemostatic sealants, platelet rich wound healants, and other wound treating compositions.Type: ApplicationFiled: October 8, 2009Publication date: April 8, 2010Inventors: Syed F. Mohammad, Sivaprasad Sukavaneshvar
-
Publication number: 20100086530Abstract: This is a new, novel, natural, relatively non-invasive and non-toxic method for the shrinkage and necrosis of cancerous cells, tumors, glands, organs, metastases processes or unwanted growths in human or animal patients. A patient's or other donor's blood is aged and processed which results in the loss of its blood vessel dilating component, nitric oxide. In addition to the loss of the vessel dilating component the other components of the blood become stiffer, stickier and sludgier. This processed blood is to then be directed by injection or catheter into the newly formed, fine, fragile, deranged and disorganized micro-capillaries of the patients cancerous tumors or unwanted growths or into the arteries that feed them nutrients and oxygen. The processed blood blocks, clogs or clots these super-fine micro-vessels and their wasteline pathways thereby causing the cancerous tumors or unwanted growths to shrink and die.Type: ApplicationFiled: September 29, 2009Publication date: April 8, 2010Inventor: Norman P. Martinov
-
Publication number: 20100061937Abstract: Erythrocytes exposed to dialysis with an hypotonic buffer stably take up superparamagnetic iron oxide nanoparticles and may be used MRI contrast agents. Such erythrocytes may also be used as drug delivery vehicles.Type: ApplicationFiled: July 3, 2007Publication date: March 11, 2010Inventors: Mauro Magnani, Antonella Antonelli
-
Publication number: 20100051025Abstract: Compositions and methods for preventing or reducing vasoconstriction in a mammal following administration of an artificial oxygen carrier (e.g., a hemoglobin-based oxygen carrier) are disclosed. The methods include administering to a mammal a composition containing an artificial oxygen carrier in combination with one or more of a nitric oxide-releasing compound, a therapeutic gas containing gaseous nitric oxide, a phosphodiesterase inhibitor, and/or a soluble guanylate cyclase sensitizer.Type: ApplicationFiled: November 6, 2007Publication date: March 4, 2010Applicant: The General Hospital CorporationInventors: Warren M. Zapol, Binglan Yu, Fumito Ichinose